Cassava Sciences Begins Cognition Maintenance Study in Alzheimer's disease
09:43 AM EDT, 05/10/2021 (MT Newswires) -- Cassava Sciences, Inc (SAVA) has initiated a cognition maintenance study to evaluate drug candidate simufilam, which is intended to reduce neurodegeneration and neuroinflammation, in patients with Alzheimer's disease.
"We've observed good safety and cognitive improvements in study participants treated with open-label simufilam," said CEO Remi Barbier. "We believe clinical data from the CMS may inform the benefit-risk assessments that drive regulatory decisions."
The biotechnology company said its strategic focus for 2021 is to advance simufilam in a phase 3 program in Alzheimer's disease, and to complete clinical readiness activities in support of the program.
Shares of Cassava Sciences were down 2.1% just after the opening bell.
Price: 40.45, Change: -0.98, Percent Change: -2.37